Possible meanings:

.

NBD-TMA ([2-(4-nitro-2,1,3-benzoxadiazol-7-yl)aminoethyl]trimethylammonium) is a small, positively charged (+1) fluorescent dye. It was also known as EAM-1 (N,N,N,-Trimethyl-2[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]ethanaminium iodide) when it was briefly supplied by Macrocyclics Company as an iodide complex.

NBD-TMA has an excitation maximum at 458 nm and an emission maximum at 530 nm. It also has a smaller local excitation maximum around 343 nm. The molar extinction coefficient is about 13,000 cm⁻¹M⁻¹ and its overall effective fluorescence is about 1% that of fluorescein. It is only mildly sensitive to halide ion collision quenching.

NBD-TMA was designed as a probe for monitoring renal transport of organic cations. As a small, positively charged fluorophore, it has also seen use as a tracer for measuring gap junction coupling in cases of cation selective connexin channels.

Further reading

EAM-2201 (4'-ethyl-AM-2201, 5"-fluoro-JWH-210) is a drug that presumably acts as a potent agonist for the cannabinoid receptors. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in July 2012 as an ingredient in synthetic cannabis smoking blends Like the closely related MAM-2201 which had been first reported around a year earlier, EAM-2201 thus appears to be another novel compound invented by designer drug suppliers specifically for recreational use. Structurally, EAM-2201 is a hybrid of two known cannabinoid compounds JWH-210 and AM-2201, both of which had previously been used as active ingredients in synthetic cannabis blends before being banned in many countries.

Pharmacology

Nothing has been published on the pharmacology of EAM-2201, though it presumably has similar properties to the closely related AM-2201 and JWH-210, which are both full agonists and unselectively bind to CB₁ and CB₂ cannabinoid receptors with low nanomolar affinity.